Department of Radiology, University of California, Los Angeles, CA, USA.
Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA.
J Gen Intern Med. 2023 Aug;38(11):2584-2592. doi: 10.1007/s11606-023-08043-4. Epub 2023 Feb 7.
Breast cancer risk models guide screening and chemoprevention decisions, but the extent and effect of variability among models, particularly at the individual level, is uncertain.
To quantify the accuracy and disagreement between commonly used risk models in categorizing individual women as average vs. high risk for developing invasive breast cancer.
Comparison of three risk prediction models: Breast Cancer Risk Assessment Tool (BCRAT), Breast Cancer Surveillance Consortium (BCSC) model, and International Breast Intervention Study (IBIS) model.
Women 40 to 74 years of age presenting for screening mammography at a multisite health system between 2011 and 2015, with 5-year follow-up for cancer outcome.
Comparison of model discrimination and calibration at the population level and inter-model agreement for 5-year breast cancer risk at the individual level using two cutoffs (≥ 1.67% and ≥ 3.0%).
A total of 31,115 women were included. When using the ≥ 1.67% threshold, more than 21% of women were classified as high risk for developing breast cancer in the next 5 years by one model, but average risk by another model. When using the ≥ 3.0% threshold, more than 5% of women had disagreements in risk severity between models. Almost half of the women (46.6%) were classified as high risk by at least one of the three models (e.g., if all three models were applied) for the threshold of ≥ 1.67%, and 11.1% were classified as high risk for ≥ 3.0%. All three models had similar accuracy at the population level.
Breast cancer risk estimates for individual women vary substantially, depending on which risk assessment model is used. The choice of cutoff used to define high risk can lead to adverse effects for screening, preventive care, and quality of life for misidentified individuals. Clinicians need to be aware of the high false-positive and false-negative rates and variation between models when talking with patients.
乳腺癌风险模型指导着筛查和化学预防决策,但模型之间的差异程度和影响,特别是在个体层面上,尚不确定。
定量评估三种常用风险模型在将个体女性归类为发展浸润性乳腺癌的平均风险与高风险方面的准确性和差异。
三种风险预测模型的比较:乳腺癌风险评估工具(BCRAT)、乳腺癌监测联盟(BCSC)模型和国际乳腺干预研究(IBIS)模型。
2011 年至 2015 年间在多地点卫生系统进行筛查乳房 X 线摄影的 40 至 74 岁女性,随访 5 年以评估癌症结局。
在人群水平上比较模型的区分度和校准度,以及在个体水平上使用两个截止值(≥1.67%和≥3.0%)对 5 年乳腺癌风险的模型间一致性。
共纳入 31115 名女性。当使用≥1.67%的截止值时,一个模型将超过 21%的女性归类为在未来 5 年内有较高乳腺癌发病风险,但另一个模型则将其归类为平均风险。当使用≥3.0%的截止值时,模型间在风险严重程度上有超过 5%的不一致。近一半的女性(46.6%)至少被三个模型中的一个(例如,如果应用所有三个模型)归类为高危(≥1.67%的截止值),11.1%被归类为高危(≥3.0%)。三个模型在人群水平上的准确性相当。
个体女性的乳腺癌风险估计值差异很大,这取决于所使用的风险评估模型。用于定义高危的截止值的选择可能会对筛查、预防保健和错误识别个体的生活质量产生不利影响。临床医生在与患者交流时需要意识到高假阳性和假阴性率以及模型之间的差异。